tbuckley/cabot-search huggingface dataset:
Quality of life in patients of carcinoma cervix treated with chemoradiotherapy: A prospective study.
Authors: Pavankumar Lachi, Monica Malik, Kesava Ramgopal Adavikolanu, Syedakram Kothwal, Deepajoseph M, Fayaz ahmed Syed, Suresh Pamidighantam, Jagannathraonaidu K.V
Journal: Journal of Clinical Oncology (2013)

e16545 Background: The standard of care in locally advanced carcinoma cervix is concurrent chemoradiotherapy. The aim of the study is to prospectively assess quality of life (QoL) in patients of carcinoma cervix treated with chemoradiotherapy. Methods: Between June 2011 and June 2012, 20 patients of carcinoma cervix were included in the study. All patients received conformal external beam radiotherapy (EBRT) on Linear accelerator to a total dose of 50Gy, 2 Gy per fraction, 25 fractions to the pelvis and intracavitary brachytherapy by High dose rate brachytherapy, 7 Gy per fraction, 3 fractions to a total dose of 21 Gy. Patients received concurrent chemotherapy with Cisplatin 40 mg/m 2 weekly for five weeks. QoL was assessed using EORTC QLQ-C30 and QLQ-C24 questionnaires at baseline and at six months following completion of treatment. The collected data was analyzed using standard statistical software package (SPSS version 20.0). Results: Median age of the patients in the study was 52years ( range 34 – 69 years), 13 (65%) patients were stage II and seven (35%) were stage III. Mean duration of treatment is 37 days (range 34- 70 days). Local control rate at six months was 95%. Compliance with completion of QoL scores was high. A statistically significant improvement (p = 0.001) was seen at six months post treatment in Global health score and in function scales like physical function, role function, emotional function, social function and cognitive function. There was a significant improvement in symptom scales of urologic and vaginal symptoms. The difference in sexual function at six months showed a trend towards significance (p = 0.052). Conclusions: Patients of carcinoma cervix have a significant improvement in quality of life following treatment with radiotherapy and chemotherapy.
Cluster-randomized trial of early palliative care for patients with metastatic cancer.
Authors: Camilla Zimmermann, Nadia Swami, Gary Rodin, Ian Tannock, Monika K. Krzyzanowska, Natasha B. Leighl, Amit M. Oza, Malcolm J. Moore, Anne Rydall, Allan Donner
Journal: Journal of Clinical Oncology (2012)

9003 Background: Patients with metastatic cancer have compromised quality of life (QOL), which tends to worsen towards the end of life. We conducted a cluster-randomized trial of early versus routine palliative care in patients with metastatic cancer, to assess impact on QOL, symptom control and satisfaction with care. Methods: Twenty-four medical oncology clinics were randomized, stratified by tumour site (4 lung clinics, 8 gastrointestinal, 4 genito-urinary, 6 breast, 2 gynecological), to intervention and follow-up (at least monthly) by a palliative care team, or to routine cancer care. Eligible patients had ECOG performance status 0-2 and a clinical prognosis of 6 months to 2 years. Patients completed measures of QOL (FACIT-Sp, including physical, social, emotional, functional and spiritual well-being; range 0-156, with higher scores indicating better QOL), symptom severity (Edmonton Symptom Assessment System; range 0-90, with higher scores indicating worse symptom severity), and satisfaction with care (FAMCARE-P16; score range 16-80) at baseline and monthly for 4 months. The primary outcome was the change in FACIT-Sp at 3 months. The planned sample size was 225 patients per arm, assuming 80% power and a 2-sided significance level of 0.05. Results: From December 2006 to September 2010, 461 patients completed baseline measures (228 intervention, 233 control); 442 patients completed at least one follow-up assessment (mean patients/cluster 18.8±11.6 control, 18.1±12.6 intervention). At 3 months, patients in the intervention group had marginally improved QOL (mean change in intervention vs. control, 1.6±14.5 vs. -2.0±13.6, p=0.07) but not symptom severity (0.1±16.9 vs. 2.1±13.9, p=0.34). At 4 months the change in QOL was more marked (2.5±15.5 vs. -4.0±14.2, p=0.008) and symptom severity was marginally better (-1.3±16.0 vs. 3.2±13.9, p=0.05). Improvement in satisfaction with care was evident at one month (p=0.001) and remained significant at both 3 months (2.3±9.1 vs.-1.8±8.2, p=0.001) and 4 months (3.7±8.6 vs. -2.4±8.3, p&lt;0.001). Conclusions: In patients with metastatic cancer, early palliative care intervention immediately improved satisfaction with care, while QOL and symptom control improved later.
A pilot phase II study of digoxin in patients with recurrent prostate cancer as evident by a rising PSA.
Authors: Jianqing Lin, Jean H. Hoffman-Censits, Danielle Duffy, Inna Chervoneva, Deborah Kilpatrick, Brooke Kennedy, Edouard John Trabulsi, Costas D. Lallas, Leonard G. Gomella, Thomas Force, William Kevin Kelly
Journal: Journal of Clinical Oncology (2013)

5061 Background: Hypoxia-inducible factor 1α (HIF-1α) is a novel cancer drug target and inhibitors of hypoxia-response pathway are being developed. Digoxin and other cardiac glycosides were found to inhibit prostate cancer (PCa) growth via the inhibition of HIF-1α synthesis in mouse model. Epidemiologic data showed that use of digoxin in men was associated with a significant lower risk of development of PCa. We hypothesized that therapeutic dose of digoxin could inhibit human PCa growth and disease progression. Methods: Open label, non-placebo pilot study. Non-metastatic, biochemically relapsed PCa patients (pts) with prostate specific antigen doubling time (PSADT) of 3 -24 months and no hormonal therapy within the past 6 months were enrolled. All pts had testosterone &gt; 50 ng/dL at baseline. Digoxin was taken daily with dose titration to therapeutic level (0.8 – 2 mg/dl) and pts had routine follow-up that include cardiac monitoring with EKG. The primary endpoint was to evaluate the proportion of patients at 6 month post-treatment that had a PSADT &gt; 200% from the baseline. Results: Fifteen pts were enrolled into the study with 13 pts finishing the planned 6 months of treatment. Twenty percent (3/15) of the pts had PSA decrease &gt;25% from baseline. At 6 months, 7 of 15 (47%) pts had PSADT &gt; 200% of the baseline PSADT and were continued on study for an additional 24 weeks of treatment. Mean duration of digoxin treatment was 34.5 weeks. Digoxin was well tolerated with possible relation of one grade 3 back pain and one grade 2 hyperglycemia. No pts came off study due to cardiac reasons. Pre-and post-treatment PSA kinetics, vascular endothelial growth factors and other cytokines levels are being determined. Conclusions: Digoxin was well tolerated and showed a prolongation in the PSDAT in 47% of the patients. Digoxin may have biologic activity in men with androgen-dependent PCa but further controlled studies are required to confirm the results. Clinical trial information: NCT01162135.
18F-DCFPyL Uptake in an Incidentally Detected Follicular Lymphoma by PET/CT Performed for Biochemically Recurrent Prostate Cancer
Authors: Dennie Meijer, Maurits Wondergem, Remco J.J. Knol, Wouter A.M. Broos, Friso M. van der Zant
Journal: Clinical Nuclear Medicine (2019)

Abstract A 75-year-old man, treated with curative intent for histopathologically proven prostate cancer (initial prostate-specific antigen, 27 ng/mL; Gleason 4 + 5 = 9) through external beam radiation therapy in 2010 in combination with 3 years of androgen deprivation therapy (leuprorelin), underwent 18 F-DCFPyL PET/CT for biochemical recurrence with a prostate-specific antigen of 4.1 ng/mL in February 2019. Multiple pelvic and some para-aortic lymph nodes showed highly increased 18 F-DCFPyL uptake, suspicious for metastases. Incidentally, a solid mesenteric mass and mesenteric lymph nodes with moderately increased 18 F-DCFPyL uptake were found. Upon histopathological evaluation, this proved to be a low-grade follicular lymphoma.
High-dose spironolactone for acne in patients with polycystic ovarian syndrome: A single-institution retrospective study
Authors: Pallavi Basu, Scott A. Elman, Boya Abudu, Ashley Beckles, Prerna Salian, Daniel A. Yanes, Martina L. Porter, Rachel V. Reynolds
Journal: Journal of the American Academy of Dermatology (2019)
Junior doctors win court appeal over how their hours were monitored
Authors: Abi Rimmer
Journal: BMJ (2019)

Junior doctors have won a Court of Appeal test case over the way their rest breaks were monitored in 2013-14. The judgment could have substantial financial implications for the NHS, so much so that the health secretary tried and failed to intervene in the case earlier this year.1

The case was brought by a group of 21 doctors, led by Sarah Hallett, deputy chair for education and training of the BMA’s Junior Doctors Committee, and was backed by the BMA.

They argued that Derby Teaching Hospitals NHS Foundation Trust breached their employment contracts by using an incorrect system to monitor rotas to check …
Ideal Cardiovascular Health Metrics and Major Cardiovascular Events in Patients With Prediabetes and Diabetes
Authors: Tiange Wang, Jieli Lu, Qing Su, Yuhong Chen, Yufang Bi, Yiming Mu, Lulu Chen, Ruying Hu, Xulei Tang, Xuefeng Yu, Mian Li, Min Xu, Yu Xu, Zhiyun Zhao, Li Yan, Guijun Qin, Qin Wan, Gang Chen, Meng Dai, Di Zhang, Zhengnan Gao, Guixia Wang, Feixia Shen, Zuojie Luo, Yingfen Qin, Li Chen, Yanan Huo, Qiang Li, Zhen Ye, Yinfei Zhang, Chao Liu, Youmin Wang, Shengli Wu, Tao Yang, Huacong Deng, Donghui Li, Shenghan Lai, Zachary T. Bloomgarden, Lixin Shi, Guang Ning, Jiajun Zhao, Weiqing Wang
Journal: JAMA Cardiology (2019)

Whether optimal cardiovascular health metrics may counteract the risk of cardiovascular events among patients with prediabetes or diabetes is unclear.
Temporal trends in oncology product approvals in the United States, 1986–2005
Authors: D. B. Ross, K. D. Weiss, P. Keegan, R. Justice, R. Pazdur
Journal: Journal of Clinical Oncology (2006)

6131 Background: No systematic examination of temporal trends in oncology approvals in the United States (US) has been conducted. Methods: Internal databases at the US Food and Drug Administration (FDA) were queried to determine the number of first-time approvals for New Molecular Entities (NMEs) (both traditional drugs and therapeutic biologics) for oncology indications between the years 1986 and 2005, inclusive; 1986 was the first year for which database records were available for both drugs and biologics. Correlation analysis was used to analyze the data for time-dependent changes in approvals and approval rates. Results: During the period examined, 70 NMEs received first-time approval for an oncology indication ( Table ); 52 (74%) were drugs and 18 were biologics. The median annual number of approvals was 3 (range, 1 to 7); the maximum number of approvals during the period examined occurred in 2004. Statistical analysis showed a weak positive correlation between the number of oncology approvals and time, and between the proportion of applications approved as a percentage of all oncology product applications and time. Conclusions: Available data suggest that the number and rate of oncology product approvals has remained stable in the US over the last two decades. [Table: see text] No significant financial relationships to disclose.
Long-term follow-up after multiple plastic stenting for refractory pancreatic duct strictures in chronic pancreatitis
Authors: Andrea Tringali, Vincenzo Bove, Salvatore F. Vadalà di Prampero, Ivo Boškoski, Pietro Familiari, Vincenzo Perri, Guido Costamagna
Journal: Endoscopy (2019)

Abstract Background Dominant pancreatic duct strictures in chronic pancreatitis are often managed by endoscopic placement of a single plastic stent. Insertion of multiple plastic stents (MPS) has been proven to be effective in managing refractory strictures, but data are still limited. The aim of this study was to investigate the efficacy and long-term results of MPS to dilate pancreatic duct strictures in chronic pancreatitis. Methods 48 patients (34 men; mean age 44 years) with chronic pancreatitis and a single pancreatic stent through a refractory stricture in the pancreatic head underwent the following protocol: 1) removal of the single pancreatic stent; 2) balloon dilation of the stricture; 3) insertion of the maximum number of stents; 4) stent removal after 6 – 12 months. Results The median number of pancreatic plastic stents placed was 3 (diameter 7 – 11.5 Fr, length 3 – 7 cm). Five patients (10.4 %) had persistent strictures after MPS removal. During a mean follow-up of 9.5 years (0.3 – 15.5 years) after stent removal, 74.4 % (32/43) of the patients were asymptomatic, and 25.6 % (11/43) experienced pancreatitis recurrence or pancreatic type pain after a mean time of 26.4 months (8/43, 18.6 % underwent plug extraction without evidence of stricture recurrence; 3/43, 7.0 % had stricture recurrence). No major complications were recorded. Conclusion Endoscopic multiple plastic stenting of chronic pancreatitis-related pancreatic duct strictures showed satisfactory long-term results, with the option of re-treatment. This procedure can be considered an important therapeutic alternative for painful pancreatic duct strictures located in the head of the pancreas in the setting of chronic pancreatitis.
Pensions crisis: patient care is being affected, doctors warn
Authors: Elisabeth Mahase
Journal: BMJ (2019)

Doctors have raised concerns that an increasing reliance on outsourcing of radiology work to private companies because of the pensions crisis is putting patients at risk.

In examples given to the Hospital Consultants and Specialists Association (HCSA) and seen by The BMJ , consultants reported that their hospitals are outsourcing more imaging checks, which some said were “worse quality” meaning they have to be re-reviewed by consultants, creating even more work.

The pensions row is the result of an inflexible pension scheme, which means that the highest earning consultants contribute 14.5% of their pensionable pay each month—something they cannot control. They then face large tax bills because they end up exceeding the pensions allowance. Many consultants have cut their clinical hours or plan early retirement as a result.

Health secretary Matt Hancock stepped in last month, urging doctors not to take early retirement because of tax charges and promising to consult with the profession and the treasury to fix this “very serious” problem by the start of the next financial year.1

The profession has also been offered a plan that would let them halve their pension contributions to avoid big tax bills, however this …
Inactivation of Proprotein Convertases in T Cells Inhibits PD-1 Expression and Creates a Favorable Immune Microenvironment in Colorectal Cancer
Authors: Mercedes Tomé, Angela Pappalardo, Fabienne Soulet, José Javier López, Jone Olaizola, Yannick Leger, Marielle Dubreuil, Amandine Mouchard, Delphine Fessart, Frédéric Delom, Vincent Pitard, Dominique Bechade, Mariane Fonck, Juan Antonio Rosado, François Ghiringhelli, Julie Déchanet-Merville, Isabelle Soubeyran, Geraldine Siegfried, Serge Evrard, Abdel-Majid Khatib
Journal: Cancer Research (2019)

Proprotein convertases (PC) activate precursor proteins that play crucial roles in various cancers. In this study, we investigated whether PC enzyme activity is required for expression of the checkpoint protein programmed cell death protein 1 (PD-1) on cytotoxic T lymphocytes (CTL) in colon cancer. Although altered expression of the PC secretory pathway was observed in human colon cancers, only furin showed highly diffuse expression throughout the tumors. Inhibition of PCs in T cells using the general protein-based inhibitor α1-PDX or the pharmacologic inhibitor Decanoyl-Arg-Val-Lys-Arg-chloromethylketone repressed PD-1 and exhausted CTLs via induction of T-cell proliferation and apoptosis inhibition, which improved CTL efficacy against microsatellite instable and microsatellite stable colon cancer cells. In vivo, inhibition of PCs enhanced CTL infiltration in colorectal tumors and increased tumor clearance in syngeneic mice compared with immunodeficient mice. Inhibition of PCs repressed PD-1 expression by blocking proteolytic maturation of the Notch precursor, inhibiting calcium/NFAT and NF-κB signaling, and enhancing ERK activation. These findings define a key role for PCs in regulating PD-1 expression and suggest targeting PCs as an adjunct approach to colorectal tumor immunotherapy. SIGNIFICANCE: Protein convertase enzymatic activity is required for PD-1 expression on T cells, and inhibition of protein convertase improves T-cell targeting of microsatellite instable and stable colorectal cancer. GRAPHICAL ABSTRACT: http://cancerres.aacrjournals.org/content/canres/79/19/5008/F1.large.jpg.
Sustained virological response from interferon-based hepatitis C regimens is associated with reduced risk of extrahepatic manifestations
Authors: Carmine Rossi, Dahn Jeong, Stanley Wong, Geoffrey McKee, Zahid Ahmad Butt, Jane Buxton, Jason Wong, Maryam Darvishian, Sofia Bartlett, Hasina Samji, Amanda Yu, Mawuena Binka, Maria Alvarez, Prince Asumadu Adu, Mark Tyndall, Mel Krajden, Naveed Zafar Janjua
Journal: Journal of Hepatology (2019)
Body composition in head and neck cancer patients undergoing concurrent chemoradiation.
Authors: Lauren Azure Zatarain, Barbara A. Murphy, Mary S. Dietrich, Heidi J. Silver, Jill Gilbert, Sheila H Ridner, Anthony Cmelak
Journal: Journal of Clinical Oncology (2013)

e20531 Background: We report results of a randomized pilot study assessing the impact of amifostine and a low weight tailored resistance exercise (LWTRE) on body composition in head and neck cancer (HNC) patients undergoing concurrent chemoradiation (CCR). Methods: Forty patients with stage III-IVB HNC scheduled for primary or adjuvant CCR were enrolled. Patients underwent primary randomization to CCR +/- amifostine and secondary randomization to nutrition counseling +/- LWTRE. IV amifostine was administered prior to radiation. Nutritional counseling and LWTRE began day 1 of CCR and continued through month 6 post-CCR. Weight was obtained at baseline, 1, 3 and 6-months post-CCR. Patients underwent lean mass measures by dual-energy X-ray absorptiometry (DEXA) at baseline, 1 and 3 months post-CCR. Results: Mean weight loss (WL) was 11.6 ± 6.3 kg (p &lt; 0.001) from baseline to 6 months post-CCR. Mean lean mass loss (LML) was 3.5 ± 3.0 kg (p&lt; 0.001) from baseline to 3 months post-CCR. The greatest change occurred from baseline to 1-month post-CCR: 10% and 7% decrease in weight and lean mass respectively. The LWTRE was feasible and safe (no adverse events). Neither amifostine nor LWTRE impacted weight or lean mass loss. Conclusions: Results failed to demonstrate decline in WL/LML with either intervention. Data confirmed WL/LML as profound acute treatment toxicity. It underscored the protracted course of WL/LML. LML has been shown to predict clinical outcomes such as reduced functionality leading to decreased quality of life. Long term follow-up of patients is needed to clearly understand the trajectory and sequellae of body composition changes in HNC patients post-CCR. Novel interventions must be designed and tested to prevent LML. Clinical trial information: NCT00503776. [Table: see text]
Long Term Follow up and Impact of Comorbidity Prior to Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Relapsed or Refractory AML - Lessons Learned from the Prospective Bridge Trial -
Authors: Jan Moritz Middeke, Regina Herbst, Stefani Barbara Parmentier, Gesine Bug, Mathias Hänel, Gernot Stuhler, Kerstin Schäfer-Eckart, Wolf Rösler, Stefan A. Klein, Wolfgang Bethge, Nael Alakel, Markus Schaich, Anke Morgner, Michael Kramer, Katja Sockel, Malte von Bonin, Friedrich Stölzel, Uwe Platzbecker, Christoph Röllig, Christian Thiede, Gerhard Ehninger, Martin Bornhäuser, Johannes Schetelig
Journal: Blood (2016)
Acute Photodistributed Exanthematous Pustulosis Associated With Liraglutide Treatment
Authors: Anna L. Cogen, Krisha Desai, David Elder, Misha Rosenbach
Journal: JAMA Dermatology (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Dermatology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Dermatology journal
Therapeutic Targeting of RNA Splicing Catalysis through Inhibition of Protein Arginine Methylation
Authors: Jia Yi Fong, Luca Pignata, Pierre-Alexis Goy, Kimihito Cojin Kawabata, Stanley Chun-Wei Lee, Cheryl M. Koh, Daniele Musiani, Enrico Massignani, Andriana G. Kotini, Alex Penson, Cheng Mun Wun, Yudao Shen, Megan Schwarz, Diana HP. Low, Alexander Rialdi, Michelle Ki, Heike Wollmann, Slim Mzoughi, Florence Gay, Christine Thompson, Timothy Hart, Olena Barbash, Genna M. Luciani, Magdalena M. Szewczyk, Bas J. Wouters, Ruud Delwel, Eirini P. Papapetrou, Dalia Barsyte-Lovejoy, Cheryl H. Arrowsmith, Mark D. Minden, Jian Jin, Ari Melnick, Tiziana Bonaldi, Omar Abdel-Wahab, Ernesto Guccione
Journal: Cancer Cell (2019)